GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival

被引:204
作者
Sonderegger, Ivo [1 ]
Iezzi, Giandomenica [1 ]
Maier, Reinhard [2 ]
Schmitz, Nicole [3 ]
Kurrer, Michael [4 ]
Kopf, Manfred [1 ]
机构
[1] ETH, Inst Integrat Biol, CH-8952 Zurich, Switzerland
[2] Kantonal Hosp, Res Dept, CH-9007 St Gallen, Switzerland
[3] Cytos Biotechnol AG, CH-8952 Schlieren, Switzerland
[4] Univ Zurich, Dept Pathol, CH-8091 Zurich, Switzerland
关键词
D O I
10.1084/jem.20071119
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Granulocyte macrophage -colony stimulating factor (GM-CSF) is critically involved in development of organ-related autoimmune inflammatory diseases including experimental allergic encephalitis and collagen-induced arthritis. Roles of GM-CSF in the initiation and in the effector phase of the autoimmune response have been proposed. Our study was designed to investigate the mechanisms of GM-CSF in autoimmunity using a model of autoimmune heart inflammatory disease (myocarditis). The pathological sequel after immunization with heart myosin has been shown previously to depend on IL-1, IL-6, IL-23, and IL-17. We found that innate GM-CSF was critical for IL-6 and IL-23 responses by dendritic cells and generation of pathological Th17 cells in vivo. Moreover, GM-CSF promoted autoimmunity by enhancing IL-6 -dependent survival of antigen specific CD4(+) T cells. These results suggest a novel role for GM-CSF in promoting generation and maintenance of Th17 cells by regulation of IL-6 and IL-23 in vivo.
引用
收藏
页码:2281 / 2294
页数:14
相关论文
共 61 条
[1]   Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-γ-independent pathway [J].
Afanasyeva, M ;
Wang, Y ;
Kaya, Z ;
Stafford, EA ;
Dohmen, KM ;
Akha, AAS ;
Rose, NR .
CIRCULATION, 2001, 104 (25) :3145-3151
[2]   Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].
Atreya, R ;
Mudter, J ;
Finotto, S ;
Müllberg, J ;
Jostock, T ;
Wirtz, S ;
Schütz, M ;
Bartsch, B ;
Holtmann, M ;
Becker, C ;
Strand, D ;
Czaja, J ;
Schlaak, JF ;
Lehr, HA ;
Autschbach, F ;
Schürmann, G ;
Nishimoto, N ;
Yoshizaki, K ;
Ito, H ;
Kishimoto, T ;
Galle, PR ;
Rose-John, S ;
Neurath, MF .
NATURE MEDICINE, 2000, 6 (05) :583-588
[3]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[4]   Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells [J].
Batten, Marcel ;
Li, Ji ;
Yi, Sothy ;
Kljavin, Noelyn M. ;
Danilenko, Dimitry M. ;
Lucas, Sophie ;
Lee, James ;
de Sauvage, Frederic J. ;
Ghilardi, Nico .
NATURE IMMUNOLOGY, 2006, 7 (09) :929-936
[5]  
Betti M, 2006, ANN ONCOL, V17, P235
[6]  
BRACIAK TA, 1993, J IMMUNOL, V151, P5145
[7]  
Campbell IK, 1998, J IMMUNOL, V161, P3639
[8]   Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis [J].
Chen, Y ;
Langrish, CL ;
Mckenzie, B ;
Joyce-Shaikh, B ;
Stumhofer, JS ;
McClanahan, T ;
Blumenschein, W ;
Churakovsa, T ;
Low, J ;
Presta, L ;
Hunter, CA ;
Kastelein, RA ;
Cua, DJ .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1317-1326
[9]   Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease [J].
Cook, AD ;
Braine, EL ;
Campbell, IK ;
Rich, MJ ;
Hamilton, JA .
ARTHRITIS RESEARCH, 2001, 3 (05) :293-298
[10]   Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain [J].
Cua, DJ ;
Sherlock, J ;
Chen, Y ;
Murphy, CA ;
Joyce, B ;
Seymour, B ;
Lucian, L ;
To, W ;
Kwan, S ;
Churakova, T ;
Zurawski, S ;
Wiekowski, M ;
Lira, SA ;
Gorman, D ;
Kastelein, RA ;
Sedgwick, JD .
NATURE, 2003, 421 (6924) :744-748